Study of Probenecid for Controlling Cluster Seizures in Patients with Focal Epilepsy During Pre-surgical Video-EEG Monitoring

2 1 1

What is this study about?

This study focuses on patients with focal epilepsy who require monitoring in specialized units. The research evaluates the effectiveness of probenecid, a medication that will be tested against a placebo to help control seizures that occur in clusters. Cluster seizures happen when a person experiences two or more seizures within a short time period during hospital monitoring.

The study examines how well probenecid works in stopping additional seizures when patients are undergoing special brain monitoring with video-EEG. During this monitoring, patients’ regular anti-seizure medications may be reduced to allow doctors to better observe and record their seizures. The medication or placebo will be given by mouth when cluster seizures occur during the monitoring period.

Doctors will observe patients for 12 hours after receiving the study medication to see if it prevents more seizures from occurring. They will also monitor other important factors such as changes in brain electrical activity, heart rate, blood pressure, and any side effects that might occur. The monitoring includes continuous recording of both video and brain wave patterns to ensure accurate observation of any seizure activity.

1 Initial admission to monitoring unit

You will be admitted to the Epilepsy Monitoring Unit (EMU) for video-EEG recording.

Your regular anti-seizure medication may be reduced to allow seizures to occur for evaluation purposes.

2 Monitoring period begins

You will be continuously monitored through video recording and EEG (brain electrical activity measurement).

The monitoring will track any seizures that occur during your stay.

3 Medication administration

If you experience two or more seizures within 6 hours (called a cluster seizure), you will receive either:

Probenecid (Santuril) 500mg tablet taken by mouth, or

– A placebo tablet (inactive substance) taken by mouth

4 Post-medication monitoring

You will be monitored for 12 hours after receiving the medication.

Medical staff will track:

– Any additional seizures

– Your heart rate and blood pressure for the first 2 hours

– Any side effects or complications

5 Extended observation

Monitoring will continue to record:

– Brain activity between seizures

– Any additional seizures that may occur

– Any need for additional anti-seizure medications

Who Can Join the Study?

  • Age between 6 and 50 years old
  • Weight requirements:
    – Children must weigh at least 20 kg
    – Adults must weigh more than 50 kg
  • Must have focal seizures (seizures that start in one specific area of the brain)
  • Need to undergo video-EEG monitoring (a test that records brain activity and video of seizures) as part of pre-surgical evaluation
  • Must be able to take medication by mouth
  • Must be able to stay under observation for at least 12 hours after experiencing a second seizure in a cluster (multiple seizures occurring close together)
  • Must be willing and able to provide informed consent to participate:
    – Adults must sign consent forms themselves
    – For children, both parents/guardians must provide written consent
  • Must have active social security coverage

Who Cannot Join the Study?

  • History of severe allergic reactions or hypersensitivity to perampanel or similar medications
  • Pregnant women or those planning pregnancy during the study period (pregnancy test required)
  • Currently breastfeeding mothers
  • Severe liver problems or abnormal liver function tests
  • Severe kidney disease or impaired kidney function
  • History of serious psychiatric conditions including severe depression or suicidal thoughts
  • Active substance abuse or dependence within the past 12 months
  • Participation in another clinical trial within the last 30 days
  • Unable to follow study procedures or attend required visits
  • History of status epilepticus (prolonged seizures lasting more than 5 minutes) in the past 3 months
  • Taking medications that could interact with the study drug
  • Uncontrolled high blood pressure or serious heart conditions
  • History of non-compliance with medical treatments
  • Any condition that, in the investigator’s opinion, makes participation unsafe

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Lille Lille France
Oncopole Claudius Regaud Toulouse France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire Rouen Rouen France
Fondation A De Rothschild Paris France
Centre Hospitalier Universitaire De Rennes Rennes France
Centre Hospitalier Lyon Sud Pierre Benite France
Hopital Beaujon Clichy France
Gywgji Hwrbsivnzyn Upcwmjopxwxpi Pcsoe Puauajfrvif Ew Ntiopnykwnlv Paris France
Andwlskccb Pneudrra Hnoufiet Do Mmrnawazf Marseille France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
01.10.2025

Trial locations

Probenecid is a medication that is being studied to help control cluster seizures in patients with epilepsy. It is being tested specifically during the period when patients are reducing their regular anti-seizure medications before undergoing video-EEG monitoring. This medication may help prevent or stop multiple seizures that occur close together (cluster seizures).

Anti-Seizure Medications (ASMs) are the regular medications that patients with epilepsy take to control their seizures. In this study, these medications are temporarily reduced, which is a standard procedure before certain types of brain monitoring, but this reduction can sometimes trigger seizures.

Focal Epilepsy – A type of epilepsy where seizures begin in a specific area of the brain, affecting one particular region or side. During these seizures, a person may experience various symptoms depending on which part of the brain is involved, such as unusual sensations, involuntary movements, or changes in awareness. The seizures can occur in clusters, meaning multiple seizures happen within a short period. In focal epilepsy, electrical disturbances remain localized to one area of the brain, though sometimes they can spread to other regions. The condition can affect people of any age and may be caused by various factors including brain injury, infections, or structural abnormalities.

Trial ID:
2024-519133-29-00
Protocol code:
GHD_2024_12
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

    Recruiting

    4 1
    Investigated drugs:
    Denmark Finland Germany Greece Hungary Italy +5
  • Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

    Recruiting

    3 1 1
    Investigated drugs:
    Germany Italy Poland Spain